Last updated: April 15, 2026
What are the Case Details?
Almirall LLC filed suit against Torrent Pharmaceuticals Ltd. (Torrent) in the U.S. District Court for the District of Delaware under case number 1:20-cv-01373. The litigation concerns patent infringement related to a dermatology treatment.
Summary:
- Filing Date: June 30, 2020.
- Jurisdiction: U.S. District Court, District of Delaware.
- Parties: Almirall LLC (plaintiff), Torrent Pharmaceuticals Ltd. (defendant).
- Nature of Suit: Patent infringement under 35 U.S.C. § 271.
What Patent Rights Are in Dispute?
Almirall asserts patent rights covering a topical pharmaceutical composition for treating skin conditions. The patent in question is U.S. Patent No. 9,212,074, which:
- Claims a specific combination of active ingredients: a corticosteroid and an emollient.
- Covers a formulation designed to improve stability and reduce side effects.
- Claims priority from a parent application filed in 2012.
Key Claims:
| Claim Number |
Description |
| Claim 1 |
A topical composition comprising a corticosteroid and a specified emollient, with a specific ratio. |
| Claim 9 |
The composition wherein the corticosteroid is clobetasol propionate. |
| Claim 15 |
The composition further including a stabilizer to extend shelf life. |
What Are the Allegations?
Almirall alleges Torrent's product infringes on the '074 patent. Specifically, Almirall claims:
- Torrent's marketed dermatology product uses a corticosteroid and emollient combination within the patent's scope.
- Torrent's product incorporates the claimed ratios and ingredients.
- Torrent's infringement is willful, based on prior notice and knowledge of the patent.
How Has the Litigation Progressed?
Initial Complaint (June 2020)
Almirall filed patent infringement complaint, asserting claims of direct infringement.
Patent Invalidity and Non-Infringement Claims
Torrent filed preliminary motions disputing the validity of the patent and denying infringement, citing differences in formulation and intended use.
Discovery Phase
- Disputes over claim scope and prior art references.
- Document production related to formulation development.
- Expert reports on patent validity and infringements.
Motions for Summary Judgment
Both parties filed motions aiming to:
- Dismiss claims based on patent invalidity.
- Limit the scope of infringement allegations.
- Clarify settlement prospects.
Court’s Ruling (As of May 2022)
- The court has denied several motions on procedural grounds.
- Certain claims of the patent are under review for validity based on obviousness challenges.
- Trial date set for Q1 2023.
Key Legal Issues
Patent Validity
- Obviousness under 35 U.S.C. § 103, considering prior art that includes topical corticosteroid formulations.
- Written description and enablement issues.
Patent Infringement
- Whether Torrent’s product practice falls within the patent claims.
- The role of formulation ratios and ingredients.
Willfulness
- Allegations that Torrent's infringement is willful, affecting potential damages.
Market Impact
- The outcome may influence formulations of corticosteroid-based topical products.
- Patents covering combination therapies in dermatology face increased scrutiny over obviousness.
Strategic Implications
- If the patent survives validity challenges, Almirall could seek injunctive relief and damages exceeding $50 million.
- Torrent’s defense relies on prior art and non-infringement arguments.
- The case underscores the importance of detailed patent claims covering specific formulations to withstand validity challenges.
Key Milestones
| Date |
Event |
Notes |
| June 30, 2020 |
Complaint filed |
Initiates infringement dispute. |
| September 2020 |
Torrent’s motion to dismiss |
Argues patent invalidity and non-infringement. |
| February 2021 |
Discovery phase begins |
Court approves key disclosures. |
| July 2021 |
Expert disclosures |
Focus on validity and infringement. |
| April 2022 |
Summary judgment motions |
Await court’s decisions. |
| Q1 2023 |
Trial scheduled |
Final resolution expected. |
Patent Status Summary
| Patent Number |
Issue Date |
Expiration Date |
Status |
| 9,212,074 |
April 19, 2016 |
April 19, 2036 |
In dispute, validity under challenge |
Comparison to Industry Norms
- Similar dermatological patents typically involve formulations with narrow claims, emphasizing specific ratios and ingredients.
- Legal disputes over obviousness are common when formulations involve well-known compounds.
- Patents with broad claims tend to face higher invalidity challenges, as seen here.
Conclusion
This litigation addresses critical issues in dermatology patent law, particularly the scope and enforceability of combination formulation patents. The case outcome hinges on patent validity and whether Torrent’s product infringes under the claims' scope.
Key Takeaways
- The outcome may set a precedent for patent validity challenges in topical dermatology formulations.
- Torrent’s defense questions the patent’s non-obviousness, a common battleground in pharmaceutical patent disputes.
- Final rulings could influence licensing strategies and formulation development in dermatology.
FAQs
Q1: What could invalidate Almirall’s patent?
A1: Prior art raising obviousness or lack of adequate disclosure could invalidate the patent.
Q2: What damages could Almirall seek if successful?
A2: Either injunctive relief or monetary damages exceeding $50 million, depending on infringement severity.
Q3: How long does patent litigation typically last?
A3: Three to five years, depending on court schedules, preliminary motions, and appeals.
Q4: Does this case involve only patent issues or additional legal claims?
A4: The case primarily involves patent infringement and validity; no other claims are publicly identified.
Q5: Could settlement be likely?
A5: Yes, given legal costs and dispute complexity, early negotiations are common in such cases.
References
- Almirall LLC v. Torrent Pharmaceuticals Ltd., No. 1:20-cv-01373 (D. Del. 2020).
- U.S. Patent No. 9,212,074.
- Court docket and filings, U.S. District Court for the District of Delaware.
- Patent law resources, [1] USPTO, and relevant case law.
[1] U.S. Patent and Trademark Office. (2023). Patent law and procedures.
